InhaleRx Limited offers medical inhalation devices for the delivery of prescribed medicines in Australia and internationally.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.10|
|52 Week High||AU$0.059|
|52 Week Low||AU$0.14|
|1 Month Change||29.63%|
|3 Month Change||-4.55%|
|1 Year Change||75.00%|
|3 Year Change||41.89%|
|5 Year Change||n/a|
|Change since IPO||-73.75%|
Recent News & Updates
|IRX||AU Healthcare Services||AU Market|
Return vs Industry: IRX exceeded the Australian Healthcare Services industry which returned 39.9% over the past year.
Return vs Market: IRX exceeded the Australian Market which returned 21.1% over the past year.
Stable Share Price: IRX is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: IRX's weekly volatility (10%) has been stable over the past year.
About the Company
InhaleRx Limited offers medical inhalation devices for the delivery of prescribed medicines in Australia and internationally. Its solutions include Medihale inhaler, a sealed pod inhaler for use with medical cannabis inhaled formulations. The company was formerly known as Lifespot Health Ltd and changed its name to InhaleRx Limited in October 2021.
InhaleRx Fundamentals Summary
|IRX fundamental statistics|
Is IRX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|IRX income statement (TTM)|
|Cost of Revenue||AU$168.87k|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.0077|
|Net Profit Margin||-5,767.44%|
How did IRX perform over the long term?See historical performance and comparison
Is InhaleRx undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate IRX's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate IRX's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: IRX is unprofitable, so we can't compare its PE Ratio to the Global Healthcare Services industry average.
PE vs Market: IRX is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate IRX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: IRX is overvalued based on its PB Ratio (5.6x) compared to the AU Healthcare Services industry average (4.2x).
How is InhaleRx forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as InhaleRx has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has InhaleRx performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IRX is currently unprofitable.
Growing Profit Margin: IRX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: IRX is unprofitable, but has reduced losses over the past 5 years at a rate of 5.7% per year.
Accelerating Growth: Unable to compare IRX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IRX is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (39.5%).
Return on Equity
High ROE: IRX has a negative Return on Equity (-41.23%), as it is currently unprofitable.
How is InhaleRx's financial position?
Financial Position Analysis
Short Term Liabilities: IRX's short term assets (A$3.6M) exceed its short term liabilities (A$508.2K).
Long Term Liabilities: IRX has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: IRX is debt free.
Reducing Debt: IRX has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IRX has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: IRX has sufficient cash runway for 2.5 years if free cash flow continues to grow at historical rates of 7.9% each year.
What is InhaleRx current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IRX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IRX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IRX's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Matthew Golden serves as Chief Executive Officer at InhaleRx Limited (formerly known as Lifespot Health Ltd) since October 12, 2020. Mr. Golden is a commercial healthcare Professional with experience i...
CEO Compensation Analysis
Compensation vs Market: Matthew's total compensation ($USD135.22K) is below average for companies of similar size in the Australian market ($USD303.55K).
Compensation vs Earnings: Insufficient data to compare Matthew's compensation with company performance.
Experienced Management: IRX's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.
Experienced Board: IRX's board of directors are not considered experienced ( 0.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: IRX insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 38.5%.
InhaleRx Limited's employee growth, exchange listings and data sources
- Name: InhaleRx Limited
- Ticker: IRX
- Exchange: ASX
- Founded: 2016
- Industry: Health Care Technology
- Sector: Healthcare
- Market Cap: AU$17.689m
- Shares outstanding: 168.47m
- Website: https://inhalerx.com.au
- InhaleRx Limited
- 2 Queen Street
- Suite 103
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/21 18:20|
|End of Day Share Price||2021/10/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.